Serum PlGF and EGF are independent prognostic markers in non-metastatic colorectal cancer-Reference-Cited by-同舟云学术

Serum PlGF and EGF are independent prognostic markers in non-metastatic colorectal cancer

Published:2019-07-29 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Schölch Sebastian^ORCID,Bogner Andreas^ORCID,Bork Ulrich,Rahbari Mohammad^ORCID,Győrffy Balázs,Schneider Martin,Reissfelder Christoph,Weitz Jürgen,Rahbari Nuh N.

Funder

Deutsche Forschungsgemeinschaft

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-019-47429-5.pdf

Reference48 articles.

1. Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J Clin 65, 87–108, https://doi.org/10.3322/caac.21262 (2015).

2. Weitz, J. et al. Colorectal cancer. Lancet 365, 153–165, https://doi.org/10.1016/S0140-6736(05)17706-X (2005).

3. Cunningham, D. et al. Colorectal cancer. Lancet 375, 1030–1047, https://doi.org/10.1016/S0140-6736(10)60353-4 (2010).

4. Vantaku, V. et al. Large-scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survival. Cancer 125, 921–932, https://doi.org/10.1002/cncr.31890 (2019).

5. Jiao, L. et al. A Prospective Targeted Serum Metabolomics Study of Pancreatic Cancer in Postmenopausal Women. Cancer prevention research, https://doi.org/10.1158/1940-6207.CAPR-18-0201 (2019).

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. VEGF/VEGFR axis and its signaling in melanoma: Current knowledge toward therapeutic targeting agents and future perspectives;Life Sciences;2024-05

2. Correlation between molecular prognostic factors and bevacizumab therapeutic resistance in patients with metastatic colorectal cancer; the AVAMET study;Journal of Mind and Medical Sciences;2024-04-30

3. Circulating low density neutrophils are associated with resistance to anti‐PD1 immunotherapy in squamous head and neck cancer;Head & Neck;2023-10-04

4. CSMD1 mutation is associated with prognosis, tumor mutation burden, and immunophenotype in non-metastatic colorectal cancer;2023-05-17

5. Integrative Transcriptomics Analysis of Early-Onset and Late-Onset Colorectal Cancer;2023-05-02